Welcome to the Australian Arthritis and Autoimmune Biobank Collaborative – A3BC
One third of Australians suffer from arthritis, autoimmune or other musculoskeletal diseases, affecting adults, children and toddlers. These diseases cost Australia over $50 billion per year, account for the greatest disability, and further impact the community through substantial out-of-pocket expenses and reduced employment.
The primary scope of the A3BC research is to better understand genomic and environmental risk factors in Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS). Other diseases such as Vasculitis, Sjogren’s Syndrome, Lower Back Pain, Gout, Scleroderma and Osteoarthritis are intended for future collection.
The A3BC hopes to find a cure for RA, JIA, PsA, AS and other musculoskeletal conditions, through cutting-edge biobank-enabled and informatics-integrated translational research. Using a collaborative network of clinicians, researchers, biobanks and data analytics resources across leading institutions in each Australian State/Territory, the A3BC will make ground-breaking discoveries to guide preventive and precision medicine towards a new era of reduced disease and safer, more effective therapy.
Please view our video below to better understand the A3BC vision: